Sickle Cell Disease and Thromboembolism: New Insights on the Pathophysiology, Diagnosis, and Treatment

被引:3
|
作者
Dobie, Gasim [1 ]
机构
[1] Jazan Univ, Coll Appl Med Sci, Med Lab Technol Dept, Gizan 45142, Saudi Arabia
关键词
sickle cell disease (SCD); platelet; hydroxyurea; hemoglobin S (HbS); nephropathy pathophysiology; BONE-MARROW-TRANSPLANTATION; CORD BLOOD TRANSPLANTATION; ACUTE LUNG INJURY; VENOUS THROMBOEMBOLISM; PULMONARY-HYPERTENSION; CELLULOSE-ACETATE; VEIN THROMBOSIS; FREE SURVIVAL; TISSUE FACTOR; GENE-THERAPY;
D O I
10.7754/Clin.Lab.2023.221006
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Sickle cell disease (SCD) is a genetic hemoglobinopathy caused by the abnormal hemoglobin S (HbS) in red blood cells. As a result of its deoxygenation and polymerization, the properties and formation of red blood cells become altered, which ultimately leads to the development of SCD. Chronic inflammatory processes produced by hemolytic and vaso-occlusive episodes, define SCD clearly. These processes result in various effects, including organ damage and increased mortality in people suffering from the disease. Thromboembolism, a potentially fatal disease, is common in patients with sickle cell disease. Despite the known association between hypercoagulability and SCD, thromboembolism is often overlooked as a major complication of SCD. However, thromboembolism affects nearly one-quarter of adult patients and appears to be a risk factor for death in SCD. It has been well documented that in SCD, hemostatic alterations and thrombotic events are associated with endothelium and leukocyte activation. In SCD, inflammatory pathways play an important role in the activation of coagulation and the generation of platelet activation. Although among other mechanisms, it also involves the activation of tissue factors, the expression of adhesion molecules, and the stimulation of innate immune responses. So, mouse model studies may provide novel mechanistic pathways. These studies on mice models are yet to be applied to humans which will lead to the development of clinical lab treatments and therapeutic drugs. Additionally, SCD is a condition that responds favorably to biological treatments like gene therapy. SCD patients now have more potentially curative alternatives with recent developments in hematopoietic stem cell (HSC) transplantation and gene therapy platforms, including Lentiglobin vectors. In the present review, a discussion of the pathophysiology and thromboinflammation of sickle cell disease, along with its global burden in terms of both diagnosis and treatment, is presented.
引用
收藏
页码:1335 / 1348
页数:14
相关论文
共 50 条
  • [31] Cardiac pathophysiology in sickle cell disease
    Oluwabukola Temitope Gbotosho
    Michael Taylor
    Punam Malik
    Journal of Thrombosis and Thrombolysis, 2021, 52 : 248 - 259
  • [32] Special Issue "New Insights into Pathophysiology, Diagnosis and Treatment of Tinnitus"
    Cobo, Pedro
    Cuesta, Maria
    BRAIN SCIENCES, 2022, 12 (10)
  • [33] Coronary artery ectasia: new insights into pathophysiology, diagnosis, and treatment
    Eitan, Amnon
    Roguin, Ariel
    CORONARY ARTERY DISEASE, 2016, 27 (05) : 420 - 428
  • [34] Pathophysiology and treatment of stroke in sickle-cell disease: present and future
    Switzer, Jeffrey A.
    Hess, David C.
    Nichols, Fenwick T.
    Adams, Robert J.
    LANCET NEUROLOGY, 2006, 5 (06): : 501 - 512
  • [35] Sickle Cell Disease-Genetics, Pathophysiology, Clinical Presentation and Treatment
    Inusa, Baba P. D.
    Hsu, Lewis L.
    Kohli, Neeraj
    Patel, Anissa
    Ominu-Evbota, Kilali
    Anie, Kofi A.
    Atoyebi, Wale
    INTERNATIONAL JOURNAL OF NEONATAL SCREENING, 2019, 5 (02)
  • [36] Pulmonary Hypertension Associated with Sickle Cell Disease: Pathophysiology and Rationale for Treatment
    Raymond L. Benza
    Lung, 2008, 186 : 247 - 254
  • [37] Pulmonary hypertension associated with sickle cell disease: Pathophysiology and rationale for treatment
    Benza, Raymond L.
    LUNG, 2008, 186 (04) : 247 - 254
  • [38] Controversies in the Diagnosis and Treatment of Sickle Cell Lung Disease
    Arteta, Manuel
    Koumbourlis, Anastassios C.
    PAEDIATRIC RESPIRATORY REVIEWS, 2014, 15 (01) : 3 - 3
  • [39] A New Step in the Treatment of Sickle Cell Disease
    de Montellano, Paul R. Ortiz
    BIOCHEMISTRY, 2018, 57 (05) : 470 - 471
  • [40] New considerations in the treatment of sickle cell disease
    Reed, W
    Vichinsky, EP
    ANNUAL REVIEW OF MEDICINE, 1998, 49 : 461 - 474